158 related articles for article (PubMed ID: 37991939)
1. The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.
Lammers SWM; Geurts SME; van Hellemond IEG; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; de Graaf H; Honkoop AH; Erdkamp FLG; de Roos WK; Linn SC; Imholz ALT; Smidt ML; Vriens IJH; Tjan-Heijnen VCG
JNCI Cancer Spectr; 2023 Oct; 7(6):. PubMed ID: 37991939
[TBL] [Abstract][Full Text] [Related]
2. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
Gnant M; Pfeiler G; Stöger H; Mlineritsch B; Fitzal F; Balic M; Kwasny W; Seifert M; Stierer M; Dubsky P; Greil R; Steger G; Samonigg H; Fesl C; Jakesz R
Br J Cancer; 2013 Aug; 109(3):589-96. PubMed ID: 23868011
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE registry.
Lammers SWM; Thurisch H; Vriens IJH; Meegdes M; Engelen SME; Erdkamp FLG; Dercksen MW; Vriens BEPJ; Aaldering KNA; Pepels MJAE; van de Winkel LMH; Peters NAJB; Tol J; Heijns JB; van de Wouw AJ; Teeuwen NJA; Geurts SME; Tjan-Heijnen VCG
Breast Cancer Res Treat; 2024 Jan; 203(2):339-349. PubMed ID: 37878148
[TBL] [Abstract][Full Text] [Related]
4. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.
Dignam JJ; Wieand K; Johnson KA; Fisher B; Xu L; Mamounas EP
J Natl Cancer Inst; 2003 Oct; 95(19):1467-76. PubMed ID: 14519753
[TBL] [Abstract][Full Text] [Related]
5. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials.
Neuhouser ML; Aragaki AK; Prentice RL; Manson JE; Chlebowski R; Carty CL; Ochs-Balcom HM; Thomson CA; Caan BJ; Tinker LF; Urrutia RP; Knudtson J; Anderson GL
JAMA Oncol; 2015 Aug; 1(5):611-21. PubMed ID: 26182172
[TBL] [Abstract][Full Text] [Related]
6. Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.
Martel S; Lambertini M; Agbor-Tarh D; Ponde NF; Gombos A; Paterson V; Hilbers F; Korde L; Manukyants A; Dueck A; Maurer C; Piccart M; Moreno-Aspitia A; Desmedt C; Di Cosimo S; de Azambuja E
J Natl Compr Canc Netw; 2021 Jan; 19(2):181-189. PubMed ID: 33401235
[TBL] [Abstract][Full Text] [Related]
7. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial.
Widschwendter P; Friedl TW; Schwentner L; DeGregorio N; Jaeger B; Schramm A; Bekes I; Deniz M; Lato K; Weissenbacher T; Kost B; Andergassen U; Jueckstock J; Neugebauer J; Trapp E; Fasching PA; Beckmann MW; Schneeweiss A; Schrader I; Rack B; Janni W; Scholz C
Breast Cancer Res; 2015 Sep; 17(1):129. PubMed ID: 26385214
[TBL] [Abstract][Full Text] [Related]
8. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
9. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Sestak I; Distler W; Forbes JF; Dowsett M; Howell A; Cuzick J
J Clin Oncol; 2010 Jul; 28(21):3411-5. PubMed ID: 20547990
[TBL] [Abstract][Full Text] [Related]
10. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
Ewertz M; Gray KP; Regan MM; Ejlertsen B; Price KN; Thürlimann B; Bonnefoi H; Forbes JF; Paridaens RJ; Rabaglio M; Gelber RD; Colleoni M; Láng I; Smith IE; Coates AS; Goldhirsch A; Mouridsen HT
J Clin Oncol; 2012 Nov; 30(32):3967-75. PubMed ID: 23045588
[TBL] [Abstract][Full Text] [Related]
11. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
; Forbes JF; Cuzick J; Buzdar A; Howell A; Tobias JS; Baum M
Lancet Oncol; 2008 Jan; 9(1):45-53. PubMed ID: 18083636
[TBL] [Abstract][Full Text] [Related]
12. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Di Cosimo S; Porcu L; Agbor-Tarh D; Cinieri S; Franzoi MA; De Santis MC; Saura C; Huober J; Fumagalli D; Izquierdo M; Piccart M; Daidone MG; de Azambuja E
Breast Cancer Res; 2020 Oct; 22(1):115. PubMed ID: 33109233
[TBL] [Abstract][Full Text] [Related]
13. [Body mass index and cancer incidence:a prospective cohort study in northern China].
Guo L; Li N; Wang G; Su K; Li F; Yang L; Ren J; Chang S; Chen S; Wu S; He J; Dai M
Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Mar; 35(3):231-6. PubMed ID: 24831616
[TBL] [Abstract][Full Text] [Related]
14. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Cuzick J; Sestak I; Baum M; Buzdar A; Howell A; Dowsett M; Forbes JF;
Lancet Oncol; 2010 Dec; 11(12):1135-41. PubMed ID: 21087898
[TBL] [Abstract][Full Text] [Related]
15. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
16. Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.
Venturelli E; Orenti A; Fabricio ASC; Garrone G; Agresti R; Paolini B; Bonini C; Gion M; Berrino F; Desmedt C; Coradini D; Biganzoli E
BMC Cancer; 2018 Jun; 18(1):651. PubMed ID: 29895278
[TBL] [Abstract][Full Text] [Related]
17. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer.
Dignam JJ; Wieand K; Johnson KA; Raich P; Anderson SJ; Somkin C; Wickerham DL
Breast Cancer Res Treat; 2006 Jun; 97(3):245-54. PubMed ID: 16331345
[TBL] [Abstract][Full Text] [Related]
18. Progesterone receptor status modifies the association between body mass index and prognosis in women diagnosed with estrogen receptor positive breast cancer.
Oudanonh T; Nabi H; Ennour-Idrissi K; Lemieux J; Diorio C
Int J Cancer; 2020 May; 146(10):2736-2745. PubMed ID: 31403177
[TBL] [Abstract][Full Text] [Related]
19. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
20. Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer.
Scholz C; Andergassen U; Hepp P; Schindlbeck C; Friedl TW; Harbeck N; Kiechle M; Sommer H; Hauner H; Friese K; Rack B; Janni W
Breast Cancer Res Treat; 2015 Jun; 151(3):569-76. PubMed ID: 25962694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
